These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37553206)

  • 21. Onasemnogene abeparvovec in spinal muscular atrophy: an Australian experience of safety and efficacy.
    D'Silva AM; Holland S; Kariyawasam D; Herbert K; Barclay P; Cairns A; MacLennan SC; Ryan MM; Sampaio H; Smith N; Woodcock IR; Yiu EM; Alexander IE; Farrar MA
    Ann Clin Transl Neurol; 2022 Mar; 9(3):339-350. PubMed ID: 35170254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gene therapy for spinal muscular atrophy: the Qatari experience.
    Ali HG; Ibrahim K; Elsaid MF; Mohamed RB; Abeidah MIA; Al Rawwas AO; Elshafey K; Almulla H; El-Akouri K; Almulla M; Othman A; Musa S; Al-Mesaifri F; Ali R; Shahbeck N; Al-Mureikhi M; Alsulaiman R; Alkaabi S; Ben-Omran T
    Gene Ther; 2021 Nov; 28(10-11):676-680. PubMed ID: 34276047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy.
    Stevens D; Claborn MK; Gildon BL; Kessler TL; Walker C
    Ann Pharmacother; 2020 Oct; 54(10):1001-1009. PubMed ID: 32204605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Onasemnogene Abeparvovec in Type 1 Spinal Muscular Atrophy: A Systematic Review and Meta-Analysis.
    Pascual-Morena C; Cavero-Redondo I; Lucerón-Lucas-Torres M; Martínez-García I; Rodríguez-Gutiérrez E; Martínez-Vizcaíno V
    Hum Gene Ther; 2023 Feb; 34(3-4):129-138. PubMed ID: 36136906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching therapies: safety profile of Onasemnogene abeparvovec-xioi in a SMA1 patient previously treated with Risdiplam.
    Tosi M; Catteruccia M; Cherchi C; Mizzoni I; D'Amico A
    Acta Myol; 2022; 41(3):117-120. PubMed ID: 36349185
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Health Care Resource Utilization and Costs for Patients with Spinal Muscular Atrophy: Findings from a Retrospective US Claims Database Analysis.
    Toro W; Yang M; Georgieva M; Song W; Patel A; Jiang AX; Zhao A; LaMarca N; Dabbous O
    Adv Ther; 2023 Oct; 40(10):4589-4605. PubMed ID: 37587305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
    Strauss KA; Farrar MA; Muntoni F; Saito K; Mendell JR; Servais L; McMillan HJ; Finkel RS; Swoboda KJ; Kwon JM; Zaidman CM; Chiriboga CA; Iannaccone ST; Krueger JM; Parsons JA; Shieh PB; Kavanagh S; Tauscher-Wisniewski S; McGill BE; Macek TA
    Nat Med; 2022 Jul; 28(7):1381-1389. PubMed ID: 35715566
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel use of nusinersen as a therapeutic bridge to onasemnogene abeparvovec-xioi in a premature neonate with type 1 spinal muscular atrophy.
    Ferrante L; Melendez-Zaidi A; Lindsey W; Lotze T
    Muscle Nerve; 2022 Aug; 66(2):E8-E10. PubMed ID: 35616550
    [No Abstract]   [Full Text] [Related]  

  • 29. Advances in the Therapy of Spinal Muscular Atrophy.
    Klotz J; Tesi Rocha C; Dunaway Young S; Duong T; Buu M; Sampson J; Day JW
    J Pediatr; 2021 Sep; 236():13-20.e1. PubMed ID: 34197889
    [No Abstract]   [Full Text] [Related]  

  • 30. Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue.
    Thomsen G; Burghes AHM; Hsieh C; Do J; Chu BTT; Perry S; Barkho B; Kaufmann P; Sproule DM; Feltner DE; Chung WK; McGovern VL; Hevner RF; Conces M; Pierson CR; Scoto M; Muntoni F; Mendell JR; Foust KD
    Nat Med; 2021 Oct; 27(10):1701-1711. PubMed ID: 34608334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study.
    Weiß C; Ziegler A; Becker LL; Johannsen J; Brennenstuhl H; Schreiber G; Flotats-Bastardas M; Stoltenburg C; Hartmann H; Illsinger S; Denecke J; Pechmann A; Müller-Felber W; Vill K; Blaschek A; Smitka M; van der Stam L; Weiss K; Winter B; Goldhahn K; Plecko B; Horber V; Bernert G; Husain RA; Rauscher C; Trollmann R; Garbade SF; Hahn A; von der Hagen M; Kaindl AM
    Lancet Child Adolesc Health; 2022 Jan; 6(1):17-27. PubMed ID: 34756190
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expert recommendations and clinical considerations in the use of onasemnogene abeparvovec gene therapy for spinal muscular atrophy.
    Kichula EA; Proud CM; Farrar MA; Kwon JM; Saito K; Desguerre I; McMillan HJ
    Muscle Nerve; 2021 Oct; 64(4):413-427. PubMed ID: 34196026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-Life Outcome After Gene Replacement Therapy for Spinal Muscular Atrophy: A Multicenter Experience.
    Tokatly Latzer I; Sagi L; Lavi R; Aharoni S; Bistritzer J; Noyman I; Ginsburg M; Lev-Or A; Katzenellenbogen S; Nevo Y; Fattal-Valevski A
    Pediatr Neurol; 2023 Jul; 144():60-68. PubMed ID: 37149951
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spinal Muscular Atrophy Treatments, Newborn Screening, and the Creation of a Neurogenetics Urgency.
    Butterfield RJ
    Semin Pediatr Neurol; 2021 Jul; 38():100899. PubMed ID: 34183144
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term clinical outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy.
    Lee S; Lee YJ; Kong J; Ryu HW; Shim YK; Han JY; Woo H; Kim SY; Cho A; Lim BC; Chae JH
    Brain Dev; 2022 Apr; 44(4):287-293. PubMed ID: 35033405
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient and Caregiver Outcomes After Onasemnogene Abeparvovec Treatment: Findings from the Cure SMA 2021 Membership Survey.
    Toro W; Yang M; Georgieva M; Anderson A; LaMarca N; Patel A; Akbarnejad H; Dabbous O
    Adv Ther; 2023 Dec; 40(12):5315-5337. PubMed ID: 37776479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy.
    AlNaimi A; Hamad SG; Mohamed RBA; Ben-Omran T; Ibrahim K; Osman MFE; Abu-Hasan M
    Pediatr Pulmonol; 2023 Apr; 58(4):1004-1011. PubMed ID: 36533697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How does risdiplam compare with other treatments for Types 1-3 spinal muscular atrophy: a systematic literature review and indirect treatment comparison.
    Ribero VA; Daigl M; Martí Y; Gorni K; Evans R; Scott DA; Mahajan A; Abrams KR; Hawkins N
    J Comp Eff Res; 2022 Apr; 11(5):347-370. PubMed ID: 35040693
    [No Abstract]   [Full Text] [Related]  

  • 39. Bridging the Gap: Gene Therapy in a Patient With Spinal Muscular Atrophy Type 1.
    Costamagna G; Govoni A; Wise A; Corti S
    Neurology; 2022 Nov; 99(21):952-956. PubMed ID: 36319109
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of sputum cultures in children with spinal Muscular atrophy.
    Levine H; Nevo Y; Katz J; Mussaffi H; Chodick G; Mei-Zahav M; Stafler P; Steuer G; Bar-On O; Mantin H; Prais D; Aharoni S
    Respir Med; 2023 Apr; 209():107143. PubMed ID: 36764497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.